TIPS treatment for decompensated liver cirrhosis

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This single-center registry at Hannover Medical School enrolls patients with liver cirrhosis who undergo transjugular intrahepatic portosystemic shunt (TIPS) as part of routine care. Clinical data, laboratory results and blood samples are collected prospectively to identify factors linked to outcomes such as control of ascites, prevention of variceal bleeding, hepatic encephalopathy, and survival. No experimental treatments are given; TIPS is performed according to standard clinical practice and patients are followed over time. The aim is to refine selection criteria and management strategies to reduce complications and improve outcomes for future patients.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Liver cirrhosis
* Indication for TIPS insertion
* Treatment at the Department of Gastroenterology, Hepatology and Endocrinology of Hannover Medical School
* Informed consent

Exclusion Criteria:

* Pregnancy or Lactation
* Age \<18 years
* Lack of Informed consent
* Symptomatic anemia with Hb \<7g/dl

Where it's running

• Hannover Medical School
  Hanover, Lower Saxony, Germany Recruiting

Study contacts

• Principal investigator: Benjamin Maasoumy, PD — Hannover Medical School
• Study coordinator: Benjamin Maasoumy, PD
• Email: Maasoumy.Benjamin@mha-hannover.de
• Phone: +49 511 532-6529

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Single vs repeated cycles of G-CSF and darbepoetin in early decompensated cirrhosis

  This trial tests whether giving multiple rounds of G-CSF plus darbepoetin helps people with early decompensated cirrhosis more than a single round or standard care.

  Recruiting Institute of Liver and Biliary Sciences, India · New Delhi, National Capital Territory of Delhi · NCT07002827

• Atorvastatin plus beta-blockers for people with decompensated cirrhosis

  This pilot Phase 2 trial will test whether adding atorvastatin 20 mg to standard non‑selective beta‑blocker therapy helps adults with decompensated cirrhosis avoid complications over 12 months.

  Recruiting Phase 2 CAMC Health System · Charleston, West Virginia · NCT06764966

• LEOPARD: Predicting liver transplant dropout with AI in European patients

  This project tests new AI-based models to predict which liver transplant candidates are at highest risk of dropout or death while on the waitlist.

  Recruiting at 4 sites Assistance Publique - Hôpitaux de Paris · Ghent, Belgium and 7 other locations · NCT06723275

• Collecting data to improve liver transplantation predictions

  This study is trying to use AI to better predict which liver transplant candidates are at risk of dropping out of the waitlist, so that more people can get fair access to transplants across Europe.

  Recruiting at 53 sites Assistance Publique - Hôpitaux de Paris · Vienna and 52 other locations · NCT06675604

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.